Birchview Capital, LP Axsome Therapeutics, Inc. Transaction History
Birchview Capital, LP
- $111 Million
- Q1 2025
A detailed history of Birchview Capital, LP transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Birchview Capital, LP holds 6,000 shares of AXSM stock, worth $659,220. This represents 0.63% of its overall portfolio holdings.
Number of Shares
6,000
Previous 4,000
50.0%
Holding current value
$659,220
Previous $338,000
106.8%
% of portfolio
0.63%
Previous 0.29%
Shares
2 transactions
Others Institutions Holding AXSM
# of Institutions
409Shares Held
36.6MCall Options Held
751KPut Options Held
568K-
Vanguard Group Inc Valley Forge, PA3.88MShares$426 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.3MShares$363 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY2.92MShares$321 Million5.58% of portfolio
-
Bvf Inc San Francisco, CA1.69MShares$186 Million8.66% of portfolio
-
Macquarie Group LTD Australia, C3976KShares$107 Million0.14% of portfolio
About Axsome Therapeutics, Inc.
- Ticker AXSM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,878,000
- Market Cap $4.71B
- Description
- Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...